Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report

Kota Shimokihara; Takashi Kawahara; Taisei Suzuki; Taku Mochizuki; Daiji Takamoto; Jun-Ichi Teranishi; Yasuhide Miyoshi; Yasushi Yumura; Masahiro Yao; Hiroji Uemura

doi:10.1002/ccr3.1328

Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report

Clin Case Rep. 2018 Jan 11;6(2):391-394. doi: 10.1002/ccr3.1328. eCollection 2018 Feb.

Affiliations

¹ Departments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.
² Department of Hematology Yokohama City University Medical Center Yokohama Japan.
³ Department of Urology Yokohama City University Graduate School of Medicine Yokohama Japan.

Abstract

Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration-resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Keywords: Castration‐resistant prostate cancer; lenalidomide; thalidomide.

Publication types

Case Reports